Sugi Predict

Sugi Predict / Compounds / SCHEMBL2247475

SCHEMBL2247475

SCHEMBL2247475

CCOc1ccc(CCC[C@@H](C(=O)N2CCN(c3ccc(Cl)cc3)CC2)[C@@H]2OC(C)(C)OC2=O)cc1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.42
▸ TP53 P04637 2/20 0.42
▸ ACACB O00763 1/20 0.41
▸ ENPP2 Q13822 2/20 0.40
▸ KMT2A Q03164 5/20 0.40
▸ MEN1 O00255 3/20 0.40
▸ ME2 P23368 1/20 0.40
▸ ME1 P48163 1/20 0.40
▸ ME3 Q16798 1/20 0.40
▸ MAPT P10636 5/20 0.39
▸ PKM P14618 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ CYP2C9 P11712 1/20 0.37
▸ HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2249495 0.93 ACACB (0.41) LMNAACACBENPP2KMT2AMEN1
SCHEMBL8270754 0.93 ACACB (0.41) LMNAACACBENPP2KMT2AMEN1
SCHEMBL2250334 0.90 ME2 (0.40) LMNATP53KMT2AMEN1ME2
SCHEMBL2248042 0.89 MAPT (0.38) LMNATP53ACACBKMT2AMEN1
SCHEMBL2551732 0.89 MC4R (0.36) LMNATP53KMT2AMEN1MAPT
SCHEMBL2248065 0.89 MC4R (0.36) LMNATP53KMT2AMEN1MAPT
SCHEMBL1828390 0.88 ALDH1A1 (0.41) TP53ACACBKMT2AMEN1MAPT
SCHEMBL2247755 0.88 ADORA2A (0.35) LMNATP53ACACBKMT2AMEN1
SCHEMBL2247586 0.86 TGM2 (0.37) LMNATP53ACACBKMT2AMEN1
SCHEMBL2244670 0.86 ADORA3 (0.43) LMNAKMT2AMEN1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8247437-B2 N-hydroxyamide derivatives and use thereof MERCK SERONO SA (CH) 2012-08-21 — — US disclosed
US-20110263628-A1 N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2011-10-27 — — US disclosed
US-8008302-B2 ((2S,3S) N,2-dihydroxy-5-methyl-3-{[4-(2-pyridinyl)-1-piperazinyl]carbonyl}hexanamide; for treatment and/or prevention of disorders related to autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, stroke, cancer, pre-term labor, endometriosis MERCK SERONO SA (CH) 2011-08-30 — — US disclosed
US-20080021028-A1 N-Hydroxyamide Derivatives and Use Thereof APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2008-01-24 — — US disclosed
EP-1771421-A1 N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF Applied Research Systems ARS Holding N.V. (AN) 2007-04-11 — — EP disclosed
WO-2006010751-A1 N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2006-02-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263628-A1 N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF HNMT, HCAR2, HPGD LMNA 1497/4885TP53 2392/4885ACACB 706/4885
US-20080021028-A1 N-Hydroxyamide Derivatives and Use Thereof HCAR2, HNMT, HPGD LMNA 1655/4885TP53 2496/4885ACACB 687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.